Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$17.40M+410.74%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Hadar Levy
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 129
- Beta
- 0.15
- Country
- IL
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 7.25
Financials
Revenue
$17.40M+410.7%Net Income
$2.76MEBITDA
$2.88MFree Cash Flow
$5.46MEPS (diluted)
$0.14Shares Outstanding (diluted)
20.06M+38.5%Operating Expenses
$10.55MCash & Debt
$62.36MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $52.23M | $7.63M | $0.40 |
| 2024 | $41.02M | $2.92M | $0.09 |
| 2023 | $31.79M | $-4.20M | $-0.13 |
| 2022 | $27.18M | $-13.35M | $-0.43 |
| 2021 | $29.66M | $-6.46M | $-0.21 |
| 2020 | $22.06M | $-5.38M | $-0.24 |
| 2019 | $23.10M | $-10.33M | $-0.50 |
| 2018 | $16.40M | $-6.48M | $-0.39 |
| 2017 | $11.14M | $-7.05M | $-0.48 |
| 2016 | $11.52M | $-2.40M | $-0.17 |
| 2015 | $6.80M | $-4.09M | $-0.28 |
| 2014 | $3.38M | $-6.54M | $-0.46 |
| 2013 | $1.19M | $-7.12M | $-0.55 |
| 2012 | $364.2K | $-5.92M | $-0.49 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.59
- Implied price
- $14.11
- Return from $12.23
- 2.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $7.01 — -42.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 20 | 24 | 28 | 32 |
|---|---|---|---|---|---|
| -2.0% | -13.9% | -10.0% | -6.6% | -3.7% | -1.1% |
| 3.0% | -9.5% | -5.4% | -1.9% | 1.2% | 3.9% |
| 8.0% | -5.1% | -0.8% | 2.9% | 6.1% | 9.0% |
| 13.0% | -0.7% | 3.8% | 7.7% | 11.0% | 14.0% |
| 18.0% | 3.7% | 8.4% | 12.4% | 15.9% | 19.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
45-70.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·28d ago·Neutral
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™ Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
View source ↗ - Newszacks.com·39d ago·Positive
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High? The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newszacks.com·49d ago·Positive
Brainsway (BWAY) Upgraded to Buy: Here's Why Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
Brainsway Q2 Earnings Call Highlights Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·55d ago·Negative
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $0.12 per share
Typical surprise +40.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$0.14 vs $0.10beat
- Wed, May 13$0.12 vs $0.05beat
- Wed, Mar 11$0.14 vs $0.06beat
- Tue, Nov 11$0.04 vs $0.05miss
- Wed, Aug 13$0.05 vs $0.04beat
- Tue, May 13$0.02 vs $0.01beat
Estimates and results for BWAY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BWAY officers and directors.
- Bought
- —
- Sold
- —
0 trades
3 trades
- Moiseyev Giladsold
- Mitrany Rayten Michal Etysold
- Mitrany Rayten Michal Etysold
36 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BWAY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.